Genome Collaboration Between AstraZeneca and the University of Cambridge

A new genomics lab by the University of Cambridge and AstraZeneca will examine genes and their relationship to various health conditions such as respiratory, and metabolic diseases.

The genomics lab will equip researchers with a variety of tools such as biological and technological resources including an automated arrayed CRISPR screening platform.

The partnership, along with the U.K.’s Medical Research Council, and the U.K.’s Human Functional Genomics Initiative, will host a lab at the Milner Therapeutics Institute (MTI) at the University of Cambridge.

“The best science is founded on collaboration, and I am delighted that the Milner Therapeutics Institute is partnering with the MRC and AstraZeneca to launch this unique functional genomics laboratory,” said Tony Kouzarides, Ph.D., director and co-founder of MTI in Gen Magazine. “This collaboration “will enable sharing of expertise and resources to deliver new diagnostics and treatments for people with chronic diseases.””

The lab is expected to commence operations in 2024.